WILMINGTON, N.C., Aug. 27 PPD, Inc. (Nasdaq:PPDI) today announced that its board of directors declared a cash dividend forthe third quarter of 2007 under its annual cash dividend policy. The quarterlycash dividend will equal $0.03 per share. The record date for the thirdquarter dividend is September 14, 2007, and the payment date is September 28,2007. The annual cash dividend policy and the payment of future quarterly cashdividends under that policy are subject to the continuing determination by theboard of directors that the policy remains in the best interests of thecompany's shareholders and in compliance with applicable laws and agreements.
PPD is a leading global contract research organization providingdiscovery, development and post-approval services as well as compoundpartnering programs. Our clients and partners include pharmaceutical,biotechnology, medical device, academic and government organizations. Withoffices in 28 countries and more than 9,700 professionals worldwide, PPDapplies innovative technologies, therapeutic expertise and a commitment toquality to help its clients and partners maximize returns on their R&Dinvestments and accelerate the delivery of safe and effective therapeutics topatients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations andassumptions, including expectations and assumptions about the payment offuture dividends under the annual dividend policy, contained in this newsrelease are forward-looking statements that involve a number of risks anduncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ fromthe assumptions on which such statements are based. In addition, otherimportant factors which could cause results to differ materially include thefollowing: risks that we may not continue our dividend policy; economicconditions and outsourcing trends in the pharmaceutical, biotechnology andmedical device industries and government-sponsored research sector; success insales growth; loss of large contracts; increased cancellation rates;competition within the outsourcing industry; the ability to attract and retainkey personnel; risks associated with the development and commercialization ofdrugs, including obtaining regulatory approval and earning dilution;dependence on collaborative relationships; rapid technological advances thatmake our products and services less competitive; and the other risk factorsset forth from time to time in the SEC filings for PPD, copies of which areavailable free of charge upon request from the PPD investor relationsdepartment.Contacts: Steve Smith (Investors) +910 558 7585 [email protected]
Louise Caudle (Media) +919 462 4467 [email protected]
SOURCE PPD, Inc.